Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
But a lacklustre pipeline could stoke the need for deals.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.